Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Olys Pharma Srl holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action, which is being handled by STEVENS, MARK V. This examiner is the busiest for the company, with 1 busiest examiner pending action. As a result, the company's current prosecution efforts are entirely focused on the review and requirements of this 1 individual at the patent office.
The portfolio's current state is concentrated, featuring 1 distinct examiner and 1 distinct art unit. This suggests that the company's innovations are focused on a specific technical niche within the Biotechnology & Pharmaceuticals sector. For a patent practitioner, the presence of 1 distinct art unit simplifies the landscape, as it requires understanding the procedural norms of only one administrative group. Furthermore, having 1 distinct examiner for the 1 pending office action allows for a consistent and focused communication strategy. This streamlined profile minimizes the administrative complexity often associated with larger portfolios, as there are no competing examiner preferences or varied art unit standards to manage. The focus on 1 pending office action under 1 examiner provides a clear and direct path for the company's current intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566954 | PLURI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF NEUROGENIC INFLAMMATION | STEVENS, MARK V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566954 | PLURI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF NEUROGENIC INFLAMMATION | STEVENS, MARK V | 1613 | §103§112DP | Non-Final OA | — | Pending | Dec 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOlys Pharma Srl has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mark V Stevens has the most, with 1 of Olys Pharma Srl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
